ArticleThe Journal of clinical investigation2007
B cell depletion: a novel therapy for autoimmune diabetes?
Article in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Energy metabolism dysregulation in idiopathic inflammatory myopathies: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- The Role of Novel Immunomodulators in the Treatment of Autoimmune Hepatitis.Journal of clinical and translational hepatology · 2025Review
- The Contribution of B Cells in Autoimmune Liver Diseases.Seminars in liver disease · 2019Review
- Anti-CD20 monoclonal antibody combined with adenovirus vector-mediated IL-10 regulates spleen CD4+/CD8+ T cells and T-bet/GATA-3 expression in NOD mice.Molecular medicine reports · 2017Article
- Preemptive CD20+ B cell Depletion Attenuates Cardiac Allograft Vasculopathy in CD154-Treated Monkeys.Transplantation · 2017Article
- Vitamin D3 Suppresses Class II Invariant Chain Peptide Expression on Activated B-Lymphocytes: A Plausible Mechanism for Downregulation of Acute Inflammatory Conditions.Journal of nutrition and metabolism · 2016Article
- Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Autoimmune responses in T1DM: quantitative methods to understand onset, progression, and prevention of disease.Pediatric diabetes · 2014Review
- Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice.Frontiers in immunology · 2014Article
- Animal models of IBD: linkage to human disease.Current opinion in pharmacology · 2010Review
- TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation.Journal of leukocyte biology · 2010Article
- Autoimmune polyglandular syndromes.Nature reviews. Endocrinology · 2010Review
- Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys.The Journal of clinical investigation · 2010Article
- Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Change you can B(cell)eive in: recent progress confirms a critical role for B cells in type 1 diabetes.Current opinion in endocrinology, diabetes, and obesity · 2009Review
- Editing antigen presentation: antigen transfer between human B lymphocytes and macrophages mediated by class A scavenger receptors.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- Article
- Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.Immunologic research · 2008Article
- Parameters influencing antigen-specific immunotherapy for type 1 diabetes.Immunologic research · 2008Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune diabetes is believed to be mediated primarily by T cells. However, B cells have been implicated in the pathogenesis of the disease in NOD mice. Although preclinical studies have been limited by the absence of anti-CD20 reagents that can induce B cell depletion in mice, a clinical trial using the B cell-depleting anti-CD20 monoclonal antibody rituximab (Rituxan) is underway in type 1 diabetes patients. In this issue of the JCI, Hu et al. describe the generation of transgenic NOD mice that express human CD20 on B cells (see the related article beginning on page 3857). They show that anti-CD20 therapy induces B cell depletion in these mice and offers some level of protection against diabetes. Although many questions remain unanswered, this mouse model represents the first opportunity to evaluate the potential value of rituximab as a novel therapy for autoimmune diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.